ArticleScientific reports2026
High expression of the underexplored SLC4A11 protein-coding transcript is specific to the corneal endothelium.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Fuchs' endothelial corneal dystrophy (FECD) and congenital hereditary endothelial dystrophy (CHED) are corneal endothelial pathologies associated with SLC4A11 gene variants. The principal findings on the expression and function of SLC4A11 in the corneal endothelium have been based on studies of three major transcripts variants (v1, v2 and v3) and their protein products. We aimed to address gaps and resolve contradictions regarding the expression of SLC4A11. Our transcriptomic analysis revealed predominant expression of RefSeq-annotated protein-coding transcripts v6 and v3, but not v2 and v1, in the corneal endothelium of patients with FECD and controls. We also demonstrated the specificity of high SLC4A11 and major transcript expression to corneal endothelium. Using the 5' RACE method, we directly showed that the major transcription start site is at the beginning of v6, from which v3 with an extended 5'UTR is also transcribed. We estimated the fraction of v6 and v3 from the overall expression as 0.63 and 0.34, respectively. We also obtained evidence of full-length v6 expression in corneal endothelium and its ability to drive translation of the previously described v2M36 protein isoform. These findings provide new information on SLC4A11 gene expression and functional consequences of some genomic variants identified in patients with FECD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.